PM
PVLA

Prosight Management’s Palvella Therapeutics PVLA Stock Holding History

Prosight Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,000
Closed -$623K – 51
2026
Q1 		$623K Buy
+5,000
New +$522K 0.1% 43
2019
Q1 		– Sell
-4,161
Closed -$885K – 45
2018
Q4 		$885K Sell
4,161
-16,613
-80% -$5.15M 0.46% 32
2018
Q3 		$9.31M Buy
20,774
+3,774
+22% +$1.64M 5.19% 6
2018
Q2 		$6.89M Buy
17,000
+9,953
+141% +$4.74M 5.05% 5
2018
Q1 		$3.85M Buy
+7,047
New +$4.36M 2.41% 16

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Prosight Management's PVLA Position: Q2 2026 in Review

Prosight Management sold out of Palvella Therapeutics (PVLA) in Q2 2026, closing a stake of 5,000 shares — an estimated $623K sold.

Prosight Management first reported a position in PVLA in Q1 2018 and held it in 5 quarters. The position peaked at $9.31M in Q3 2018. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Prosight Management reported no remaining Palvella Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Prosight Management sold 5,000 Palvella Therapeutics shares in Q2 2026, an estimated $623K.
  • Prosight Management first reported a position in Palvella Therapeutics in Q1 2018 and held it in 5 quarters.
  • Prosight Management's Palvella Therapeutics position peaked at $9.31M in Q3 2018.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.